Image: Professor Ewa Goldys
Original Published Date: 
Tuesday, November 24, 2015

Breakthrough technology uncovered by the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), will be a part of a new collaboration between Macquarie University and clinical-stage regenerative medicine company Regeneus. The collaboration is set to commercialise cell selection technology that for the first time allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies. Professor Ewa Goldys, Deputy Director of the CNBP said cells can secrete pro-inflammatory cytokines, as part of the body’s sickness response mechanism or anti-inflammatory cytokines that play a role in healing. “We can regard anti-inflammatory cytokines as, in a sense, cancelling out the effects of pro-inflammatory cytokines. Our research allows us to detect which cells are most strongly pumping out specific anti-inflammatory cytokines. With this information we are a step closer to controlling and regulating the immune response in the body in a novel way, by using the selected cells. Our approach paves the way for localised immunosuppression in a wide range of diseases, including arthritis.”

Media issued by Macquarie University

Photo credit: 

Image courtesy ARC Centre of Excellence for Nanoscale BioPhotonics